News
The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...
Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...
Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...
The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...
Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted ...
A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...
California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins ...
Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and ...
REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle ...
Juvena Therapeutics Inc. co-founder and CEO Hanadie Yousef had the company’s name picked out several years before it was officially incorporated in 2017 to combine Yousef’s work in the mechanics of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results